Gabelli Funds’s Drugs Made In America Acquisition II Corp DMII Stock Holding History

Gabelli Funds’s Portfolio DMII Stock Details DMII Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.61M	Buy	+161,400	New	+$1.61M	0.01%	801

Other funds holding DMII

Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return

MMCAP International Grand Cayman, Cayman Islands $1.16B AUM 77.9% 1-Year Est. Return

KIM

Karpus Investment Management Pittsford, New York $3.21B AUM 6.83% 1-Year Est. Return

GCL

Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $62.2B AUM 31.35% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return

WAM

Wolverine Asset Management Chicago, Illinois $10.4B AUM 4.78% 1-Year Est. Return

PAMP

Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.27% 1-Year Est. Return

TCM

Tenor Capital Management New York $6.49B AUM 3.01% 1-Year Est. Return

Gabelli Funds's DMII Position: Q1 2026 in Review

Gabelli Funds opened a new position in Drugs Made In America Acquisition II Corp (DMII) in Q1 2026: 161,400 shares worth $1.61M. The stake represents 0.01% of the portfolio and ranks #801 among its holdings.

68 funds tracked by Wall St. Rank hold DMII as of Q1 2026.

Gabelli Funds held 161,400 shares of Drugs Made In America Acquisition II Corp worth $1.61M as of Q1 2026.
Drugs Made In America Acquisition II Corp was a new Gabelli Funds position in Q1 2026.
Drugs Made In America Acquisition II Corp made up 0.01% of Gabelli Funds's portfolio in Q1 2026, its #801 holding.
68 funds tracked by Wall St. Rank held Drugs Made In America Acquisition II Corp as of Q1 2026.

Based on Gabelli Funds's 13F filing for Q1 2026, filed 14 May 2026.